Erste Group Bank Decreases Earnings Estimates for Novartis

Novartis AG (NYSE:NVS) – Equities research analysts at Erste Group Bank decreased their FY2026 earnings estimates for Novartis in a research note issued on Wednesday, July 15th. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings per share of $8.90 for the year, down from their previous estimate of $9.01. The consensus estimate for Novartis’ current full-year earnings is $8.75 per share.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Monday, April 27th. The company reported $1.99 earnings per share for the quarter, missing analysts’ consensus estimates of $2.11 by ($0.12). Novartis had a return on equity of 38.82% and a net margin of 24.87%.The business had revenue of $13.52 billion during the quarter, compared to the consensus estimate of $13.44 billion. During the same quarter in the previous year, the firm posted $2.28 earnings per share. The company’s revenue was down .9% compared to the same quarter last year.

Other analysts have also issued reports about the stock. Weiss Ratings lowered shares of Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research report on Wednesday, April 29th. Morgan Stanley lifted their price objective on Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a report on Thursday, March 26th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $141.20.

Novartis Price Performance

NVS stock opened at $153.78 on Monday. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.65 and a current ratio of 0.85. The firm has a market cap of $293.44 billion, a P/E ratio of 22.03, a P/E/G ratio of 2.65 and a beta of 0.45. The firm’s fifty day moving average is $151.41 and its 200 day moving average is $151.69. Novartis has a 52 week low of $112.34 and a 52 week high of $170.46.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in NVS. J.W. Cole Advisors Inc. boosted its holdings in Novartis by 0.6% in the fourth quarter. J.W. Cole Advisors Inc. now owns 10,577 shares of the company’s stock valued at $1,348,000 after acquiring an additional 64 shares in the last quarter. Roundview Capital LLC raised its holdings in Novartis by 2.5% in the 4th quarter. Roundview Capital LLC now owns 2,711 shares of the company’s stock worth $374,000 after purchasing an additional 66 shares in the last quarter. IMA Advisory Services Inc. raised its holdings in Novartis by 10.9% in the 4th quarter. IMA Advisory Services Inc. now owns 710 shares of the company’s stock worth $98,000 after purchasing an additional 70 shares in the last quarter. Moody National Bank Trust Division lifted its position in shares of Novartis by 4.2% in the 2nd quarter. Moody National Bank Trust Division now owns 1,802 shares of the company’s stock worth $282,000 after purchasing an additional 72 shares during the period. Finally, Abundance Wealth Counselors boosted its stake in shares of Novartis by 0.4% during the 4th quarter. Abundance Wealth Counselors now owns 16,927 shares of the company’s stock valued at $2,334,000 after purchasing an additional 73 shares in the last quarter. Institutional investors own 13.12% of the company’s stock.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.